Excellent- but not unexpected. Obviously Goldseeker has been wrong in his interpretation of GCDx and their goal to become a force in the Cancer Diagnostics market.
Question: How far reaching will Mr. Gartner's reach actually be?
Answer: All the way to India, China, and Europe via RXPC and its in-place network. Living, you have always been to quick to assume the most negative- adjust your biases a bit.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.